Janus Henderson Group PLC Inhibrx, Inc. Transaction History

Janus Henderson Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $393 - $474	12 Added 0.11%	11,370 $397,000
Q4 2023 Feb 14, 2024	SELL	$14.5 - $38.0 $246 - $646	-17 Reduced 0.15%	11,358 $431,000
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $236 - $394	15 Added 0.13%	11,375 $208,000
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $525 - $862	-31 Reduced 0.27%	11,360 $294,000
Q1 2023 May 15, 2023	BUY	$18.45 - $27.14 $210,163 - $309,151	11,391 New	11,391 $214,000
Q2 2021 Aug 16, 2021	SELL	$14.69 - $27.52 $1.04 Million - $1.95 Million	-70,839 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.27 - $41.26 $286,775 - $727,248	17,626 Added 33.12%	70,839 $1.42 Million
Q4 2020 Feb 16, 2021	BUY	$15.96 - $50.0 $849,279 - $2.66 Million	53,213 New	53,213 $1.75 Million

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.